person · Reporting owner

CRANSTON MARY B

Disclosed activity across 6 companies

Tapewire entity: 11559
SEC CIK: 0001104268

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Chemours CoCC · Entity 4420	Director	August 07, 2026	August 11, 2026
Mellanox Technologies, Ltd.MLNX · Entity 13120	10% owner · See Explanation of Responses	January 22, 2018	January 24, 2018
TPG Inc.TPG · Entity 3253	Director	July 15, 2026	July 17, 2026
VISA INC.V · Entity 495	Director	January 24, 2023	January 27, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Chemours Co

Report date August 07, 2026 · Filed August 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	113,140.9469	Reported balance After 2026-08-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-08-07 · Purchase · Acquired 6,000 · Balance 113,140.9469 F1: Includes directly owned shares, restricted stock units and dividend equivalent units.

Filing footnotes · ownership attribution and instrument terms

F1: Includes directly owned shares, restricted stock units and dividend equivalent units.

Mellanox Technologies, Ltd.

Report date January 22, 2018 · Filed January 24, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, nominal value NIS 0.0175 per shareSEC Table I · non-derivative	IndirectBy Mary B. Cranston Revocable Trust UAD 05/12/2009	223	Reported balance After 2018-01-22 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2018-01-22 · Purchase · Acquired 223 · Balance 223 F1: The Reporting Person may be deemed to be a member of a Section 13(d) group that beneficially owns in the aggregate more than 10% of the Issuer's outstanding Ordinary Shares. The Reporting Person disclaims beneficial ownership of such Ordinary Shares except to the extent of her pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such Ordinary Shares for purposes of Section 16 or for any other purpose. F2: Held by the Mary B. Cranston Revocable Trust UAD 05/12/2009, of which the Reporting Person is the trustee.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person may be deemed to be a member of a Section 13(d) group that beneficially owns in the aggregate more than 10% of the Issuer's outstanding Ordinary Shares. The Reporting Person disclaims beneficial ownership of such Ordinary Shares except to the extent of her pecuniary interest therein, and this report shall not be deemed to be an admission that the Reporting Person is the beneficial owner of such Ordinary Shares for purposes of Section 16 or for any other purpose.

F2: Held by the Mary B. Cranston Revocable Trust UAD 05/12/2009, of which the Reporting Person is the trustee.

TPG Inc.

Report date July 15, 2026 · Filed July 17, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	34,958	Reported balance After 2026-07-15 transaction · row 1 1 source row Row 1 · 2026-07-15 · Grant · Acquired 4,181 · Balance 34,958 F1: Represents an annual award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs.

Filing footnotes · ownership attribution and instrument terms

F1: Represents an annual award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs.

VISA INC.

Report date January 24, 2023 · Filed January 27, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	1,050	Reported balance After 2023-01-24 transaction · row 1 1 source row Row 1 · 2023-01-24 · Grant · Acquired 1,050 · Balance 1,050
Class A Common StockSEC Table I · non-derivative	IndirectBy The Mary B. Cranston Trust 5/12/2009	10,156	Reported balance Holding disclosure · report date 2023-01-24 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 10,156

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

McAfee Corp.

Report date March 01, 2022 · Filed March 03, 2022

Section 16 reporting ended · disclosed 2022-03-03. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-03-01 transaction · row 1 1 source row Row 1 · 2022-03-01 · Disposition to issuer · Disposed 69,003 · Balance 0 F1: Certain of these securities are restricted stock units ("RSUs") that represent the Reporting Person's right to receive shares of Class A common stock of the Issuer. The RSUs and shares of Class A common stock were cancelled pursuant to that certain Merger Agreement, dated November 5, 2021, between the Issuer, Condor BidCo, Inc. and Condor Merger Sub, Inc., in exchange for a cash payment of $26.00 per share.

Filing footnotes · ownership attribution and instrument terms

F1: Certain of these securities are restricted stock units ("RSUs") that represent the Reporting Person's right to receive shares of Class A common stock of the Issuer. The RSUs and shares of Class A common stock were cancelled pursuant to that certain Merger Agreement, dated November 5, 2021, between the Issuer, Condor BidCo, Inc. and Condor Merger Sub, Inc., in exchange for a cash payment of $26.00 per share.

MyoKardia, Inc.

Report date November 17, 2020 · Filed November 20, 2020

Section 16 reporting ended · disclosed 2020-11-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-11-17 transaction · row 1 1 source row Row 1 · 2020-11-17 · Other · Disposed 4,100 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.60	Direct	Reported balance After 2020-11-17 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.00	Direct	Reported balance After 2020-11-17 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.85	Direct	Reported balance After 2020-11-17 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-11-17 · Disposition to issuer · Disposed 11,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.77	Direct	Reported balance After 2020-11-17 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-11-17 · Disposition to issuer · Disposed 6,600 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.27	Direct	Reported balance After 2020-11-17 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-11-17 · Disposition to issuer · Disposed 3,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes.

F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price.

F3: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
August 07, 2026 Filed Aug 11, 2026 20:10 UTC	Chemours Co CC · Entity 4420	PurchaseCommon Stock	6,000	$15.83	$94,950.00	Disclosure SEC source: 0001193125-26-344632 · ownership.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,140.9469 F1 · balance_after: Includes directly owned shares, restricted stock units and dividend equivalent units. Read SEC document
July 15, 2026 Filed Jul 17, 2026 21:16 UTC	TPG Inc. TPG · Entity 3253	GrantClass A Common Stock	4,181	Not disclosed	Not disclosed	Disclosure SEC source: 0000947871-26-000707 · ownership.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,958 F1 · price: Represents an annual award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs. Read SEC document
May 06, 2026 Filed May 8, 2026 20:15 UTC	Chemours Co CC · Entity 4420	GrantCommon Stock	7,182	$0.00	$0.00	Disclosure SEC source: 0001193125-26-214673 · ownership.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,830.0129 F1 · balance_after: The total holdings have been adjusted to correct an administrative error in prior Form 4s. F2 · balance_after: Includes deferred stock units and dividend equivalent units. Read SEC document
July 15, 2025 Filed Jul 17, 2025 23:31 UTC	TPG Inc. TPG · Entity 3253	GrantClass A Common Stock	2,762	Not disclosed	Not disclosed	Disclosure SEC source: 0000947871-25-000673 · ownership.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,777 F1 · shares: Represents an annual award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs. F1 · price: Represents an annual award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs. Read SEC document
April 22, 2025 Filed Apr 24, 2025 21:25 UTC	Chemours Co CC · Entity 4420	GrantCommon Stock	14,096	$0.00	$0.00	Disclosure SEC source: 0001062993-25-007917 · form4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,539.8505 F1 · balance_after: Includes directly owned shares, stock units and dividend equivalent units. Read SEC document
August 06, 2024 Filed Aug 7, 2024 20:55 UTC	Chemours Co CC · Entity 4420	GrantCommon Stock	8,547	$0.00	$0.00	Disclosure SEC source: 0001062993-24-014620 · form4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,192.4509 F1 · balance_after: Includes directly owned shares, stock units and dividend equivalent units. Read SEC document
July 15, 2024 Filed Jul 17, 2024 21:35 UTC	TPG Inc. TPG · Entity 3253	GrantClass A Common Stock	3,592	Not disclosed	Not disclosed	Disclosure SEC source: 0000947871-24-000624 · ownership.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,015 F1 · shares: Represents an annual award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs. F1 · price: Represents an annual award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs. Read SEC document
July 15, 2023 Filed Jul 18, 2023 20:10 UTC	TPG Inc. TPG · Entity 3253	GrantClass A Common Stock	5,111	Not disclosed	Not disclosed	Disclosure SEC source: 0000947871-23-000756 · ownership.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,423 F1 · shares: Represents an annual award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs. F1 · price: Represents an annual award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs. Read SEC document
April 26, 2023 Filed Apr 28, 2023 20:33 UTC	Chemours Co CC · Entity 4420	GrantCommon Stock	5,858	$0.00	$0.00	Disclosure SEC source: 0001209191-23-026047 · doc4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,648.0632 F1 · balance_after: Includes directly owned shares, stock units and dividend equivalent units. Read SEC document
January 24, 2023 Filed Jan 27, 2023 00:05 UTC	VISA INC. V · Entity 495	GrantClass A Common Stock	1,050	$0.00	$0.00	Disclosure SEC source: 0001127602-23-002385 · form4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,050 Read SEC document
July 15, 2022 Filed Jul 19, 2022 21:05 UTC	TPG Inc. TPG · Entity 3253	GrantRestricted Stock Units	9,142	Not disclosed	Not disclosed	Disclosure SEC source: 0000947871-22-000789 · ownership.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,312 F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). The Issuer has granted the RSUs pursuant to its Independent Director Compensation Policy. The RSUs represent an annual award that vests on the first anniversary of the grant date, subject to the Reporting Person's continuous service through the vesting date; provided that if the Reporting Person serves through the Issuer's next annual meeting of shareholders occurring after the date of grant, the Reporting Person will be entitled to retain the RSUs. Read SEC document
June 03, 2022 Filed Jun 7, 2022 00:45 UTC	VISA INC. V · Entity 495	GiftClass A Common Stock	940	$0.00	$0.00	Disclosure SEC source: 0001127602-22-016946 · form4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Mary B. Cranston Trust 5/12/2009 Disclosed balance after: 10,156 Read SEC document
April 27, 2022 Filed Apr 29, 2022 14:27 UTC	Chemours Co CC · Entity 4420	GrantCommon Stock	4,442	$0.00	$0.00	Disclosure SEC source: 0001627223-22-000029 · primary_doc.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,850.1931 F1 · balance_after: Includes directly owned shares, stock units and dividend equivalent units. Read SEC document
March 01, 2022 Filed Mar 3, 2022 22:30 UTC	McAfee Corp. MCFE · Entity 11636	Disposition to issuerClass A Common Stock	69,003	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-22-009140 · doc4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Certain of these securities are restricted stock units ("RSUs") that represent the Reporting Person's right to receive shares of Class A common stock of the Issuer. The RSUs and shares of Class A common stock were cancelled pursuant to that certain Merger Agreement, dated November 5, 2021, between the Issuer, Condor BidCo, Inc. and Condor Merger Sub, Inc., in exchange for a cash payment of $26.00 per share. F1 · price: Certain of these securities are restricted stock units ("RSUs") that represent the Reporting Person's right to receive shares of Class A common stock of the Issuer. The RSUs and shares of Class A common stock were cancelled pursuant to that certain Merger Agreement, dated November 5, 2021, between the Issuer, Condor BidCo, Inc. and Condor Merger Sub, Inc., in exchange for a cash payment of $26.00 per share. Read SEC document
January 25, 2022 Filed Jan 28, 2022 01:22 UTC	VISA INC. V · Entity 495	GrantRestricted Stock Units · Derivative	1,114	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-22-002332 · form4.xml · derivative · entry 2 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,114 Underlying: Class A Common Stock · 1,114 shares Expires not disclosed F1 · derivative.exercise_price: One share of Visa Inc. common stock, or the cash value thereof, will be delivered for each restricted stock unit on a future date selected by the director or after retirement or termination of service, subject to earlier settlement in limited circumstances specified in the award agreement. F1 · price: One share of Visa Inc. common stock, or the cash value thereof, will be delivered for each restricted stock unit on a future date selected by the director or after retirement or termination of service, subject to earlier settlement in limited circumstances specified in the award agreement. F1 · derivative.exercise_date: One share of Visa Inc. common stock, or the cash value thereof, will be delivered for each restricted stock unit on a future date selected by the director or after retirement or termination of service, subject to earlier settlement in limited circumstances specified in the award agreement. F1 · derivative.expiration_date: One share of Visa Inc. common stock, or the cash value thereof, will be delivered for each restricted stock unit on a future date selected by the director or after retirement or termination of service, subject to earlier settlement in limited circumstances specified in the award agreement. Read SEC document
January 13, 2022 Filed Jan 14, 2022 01:12 UTC	TPG Inc. TPG · Entity 3253	GrantRestricted Stock Units	10,170	Not disclosed	Not disclosed	Disclosure SEC source: 0000947871-22-000062 · ownership.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,170 F1 · price: Each restricted stock unit (RSU) represents a contingent right to receive one share of Class A common stock of TPG Inc. (the "Issuer"). One-third of the RSUs will vest on each of the first, second and third anniversaries of the date of grant, subject to the Reporting Person's continuous service through the vesting date. Read SEC document
August 27, 2021 Filed Aug 31, 2021 22:21 UTC	McAfee Corp. MCFE · Entity 11636	GrantClass A Common Stock	2,609	$26.77	$69,842.93	Disclosure SEC source: 0001562180-21-005676 · primarydocument.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,003 F1 · security: These additional RSUs were granted pursuant to the terms of the Reporting Person's previously reported RSU award(s) in connection with the special dividend paid to holders of record of the Issuer's Class A Common Stock as of August 13, 2021. F2 · shares: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document
June 04, 2021 Filed Jun 8, 2021 20:30 UTC	McAfee Corp. MCFE · Entity 11636	GrantClass A Common Stock	8,259	$0.00	$0.00	Disclosure SEC source: 0000899243-21-022508 · doc4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,394 F1 · balance_after: The Reporting Person has previously reported awards of Restricted Stock Units ("RSUs") in Table II of Form 4. The total reported in Column 5 includes 7,267 RSUs previously reported in Table II, and 50,868 shares of Class A common stock previously reported as beneficially owned by the Reporting Person. Read SEC document
April 29, 2021 Filed Apr 30, 2021 18:52 UTC	Chemours Co CC · Entity 4420	GrantCommon Stock	4,653	$0.00	$0.00	Disclosure SEC source: 0001627223-21-000024 · primary_doc.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,665.0623 F1 · balance_after: Includes directly owned shares, stock units and dividend equivalent units. Read SEC document
February 18, 2021 Filed Feb 19, 2021 21:16 UTC	VISA INC. V · Entity 495	SaleClass A Common Stock	4,900	$207.51	$1,016,799.00	Disclosure SEC source: 0001127602-21-006735 · form4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Mary B. Cranston Trust 5/12/2009 Disclosed balance after: 11,096 Read SEC document
January 26, 2021 Filed Jan 27, 2021 22:48 UTC	VISA INC. V · Entity 495	GrantRestricted Stock Units · Derivative	1,064	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-21-002737 · form4.xml · derivative · entry 2 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,064 Underlying: Class A Common Stock · 1,064 shares Expires not disclosed F1 · derivative.exercise_price: One share of Visa Inc. common stock, or the cash value thereof, will be delivered for each restricted stock unit on a future date selected by the director or after retirement or termination of service, subject to earlier settlement in limited circumstances specified in the award agreement. F1 · price: One share of Visa Inc. common stock, or the cash value thereof, will be delivered for each restricted stock unit on a future date selected by the director or after retirement or termination of service, subject to earlier settlement in limited circumstances specified in the award agreement. F1 · derivative.exercise_date: One share of Visa Inc. common stock, or the cash value thereof, will be delivered for each restricted stock unit on a future date selected by the director or after retirement or termination of service, subject to earlier settlement in limited circumstances specified in the award agreement. F1 · derivative.expiration_date: One share of Visa Inc. common stock, or the cash value thereof, will be delivered for each restricted stock unit on a future date selected by the director or after retirement or termination of service, subject to earlier settlement in limited circumstances specified in the award agreement. Read SEC document
December 15, 2020 Filed Dec 18, 2020 02:47 UTC	McAfee Corp. MCFE · Entity 11636	GrantRestricted Stock Units · Derivative	7,267	$0.00	$0.00	Disclosure SEC source: 0000899243-20-034400 · doc4.xml · derivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,267 Underlying: Class A Common Stock · 7,267 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A common stock. F2 · derivative.exercise_date: The RSUs vest in full on December 15, 2021. F2 · derivative.expiration_date: The RSUs vest in full on December 15, 2021. Read SEC document
December 11, 2020 Filed Dec 15, 2020 21:40 UTC	VISA INC. V · Entity 495	GiftClass A Common Stock	2,432	$0.00	$0.00	Disclosure SEC source: 0001127602-20-031369 · form4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Mary B. Cranston Trust 5/12/2009 Disclosed balance after: 15,996 Read SEC document
November 22, 2020 Filed Nov 23, 2020 21:10 UTC	McAfee Corp. MCFE · Entity 11636	Exercise / conversionRestricted Stock Units · Derivative	27,404	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031899 · doc4.xml · derivative · entry 2 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 27,404 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A common stock. F2 · derivative.exercise_date: The RSUs vested in full on November 22, 2020. F2 · derivative.expiration_date: The RSUs vested in full on November 22, 2020. Read SEC document
November 22, 2020 Filed Nov 23, 2020 21:10 UTC	McAfee Corp. MCFE · Entity 11636	Exercise / conversionClass A Common Stock	27,404	$0.00	$0.00	Disclosure SEC source: 0000899243-20-031899 · doc4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,868 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 17, 2020 Filed Nov 20, 2020 01:16 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	3,000	Not disclosed Strike: $100.27	Not disclosed	Disclosure SEC source: 0000899243-20-031748 · doc4.xml · derivative · entry 6 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 20, 2020 01:16 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	6,600	Not disclosed Strike: $47.77	Not disclosed	Disclosure SEC source: 0000899243-20-031748 · doc4.xml · derivative · entry 5 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,600 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 20, 2020 01:16 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	11,000	Not disclosed Strike: $48.85	Not disclosed	Disclosure SEC source: 0000899243-20-031748 · doc4.xml · derivative · entry 4 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 20, 2020 01:16 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	11,000	Not disclosed Strike: $14.00	Not disclosed	Disclosure SEC source: 0000899243-20-031748 · doc4.xml · derivative · entry 3 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 20, 2020 01:16 UTC	MyoKardia, Inc. MYOK · Entity 145206	Disposition to issuerStock Option (Right to buy) · Derivative	11,000	Not disclosed Strike: $13.60	Not disclosed	Disclosure SEC source: 0000899243-20-031748 · doc4.xml · derivative · entry 2 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,000 shares Expires not disclosed F3 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each Issuer option that was outstanding (whether vested or unvested) immediately prior to the Effective Time and then exercisable for a per share exercise price less than the Offer Price that would be payable in respect of the Shares underlying such Issuer option (was cancelled and automatically converted into solely the right to receive, for each Share underlying such Issuer option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of (i) the Offer Price over (ii) the per share exercise price of such Issuer option. Read SEC document
November 17, 2020 Filed Nov 20, 2020 01:16 UTC	MyoKardia, Inc. MYOK · Entity 145206	OtherCommon Stock	4,100	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-031748 · doc4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 3, 2020, by and among the Issuer, Bristol-Myers Squibb Company ("Parent"), and Gotham Merger Sub Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of November 17, 2020 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $225.00 in cash (the "Offer Price") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Pursuant to the terms of the Merger Agreement, each Issuer RSU that was outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled at the Effective Time and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the Offer Price. Read SEC document
June 30, 2020 Filed Jul 1, 2020 23:28 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionStock Option (Right to Buy) · Derivative	21,629	$0.00 Strike: $11.69	$0.00	Disclosure SEC source: 0000899243-20-018175 · doc4.xml · derivative · entry 7 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,629 shares Expires 2026-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested in 48 equal monthly installments from April 11, 2016 to April 11, 2020. Read SEC document
June 30, 2020 Filed Jul 1, 2020 23:28 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	21,329	$96.59	$2,060,178.77	Disclosure SEC source: 0000899243-20-018175 · doc4.xml · nonDerivative · entry 5 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · price: Represents the weighted average sale price of the shares sold ranging from $96.24 to $97.236 per share. Read SEC document
June 30, 2020 Filed Jul 1, 2020 23:28 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	300	$97.25	$29,176.41	Disclosure SEC source: 0000899243-20-018175 · doc4.xml · nonDerivative · entry 4 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,329 F2 · price: Represents the weighted average sale price of the shares sold ranging from $97.247 to $97.27 per share. Read SEC document
June 30, 2020 Filed Jul 1, 2020 23:28 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	21,629	$11.69	$252,843.01	Disclosure SEC source: 0000899243-20-018175 · doc4.xml · nonDerivative · entry 3 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 30, 2020 Filed Oct 31, 2020 00:56 UTC Amendment	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	21,329	$96.59	$2,060,178.77	Disclosure SEC source: 0000899243-20-030040 · doc4a.xml · nonDerivative · entry 5 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 F3 · price: Represents the weighted average sale price of the shares sold ranging from $96.24 to $97.236 per share. Read SEC document
June 30, 2020 Filed Oct 31, 2020 00:56 UTC Amendment	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	300	$97.25	$29,176.41	Disclosure SEC source: 0000899243-20-030040 · doc4a.xml · nonDerivative · entry 4 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,629 F2 · price: Represents the weighted average sale price of the shares sold ranging from $97.247 to $97.27 per share. Read SEC document
June 30, 2020 Filed Oct 31, 2020 00:56 UTC Amendment	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	21,629	$11.69	$252,843.01	Disclosure SEC source: 0000899243-20-030040 · doc4a.xml · nonDerivative · entry 3 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 29, 2020 Filed Jul 1, 2020 23:28 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionStock Option (Right to Buy) · Derivative	371	$0.00 Strike: $11.69	$0.00	Disclosure SEC source: 0000899243-20-018175 · doc4.xml · derivative · entry 6 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,629 Underlying: Common Stock · 371 shares Expires 2026-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vested in 48 equal monthly installments from April 11, 2016 to April 11, 2020. Read SEC document
June 29, 2020 Filed Jul 1, 2020 23:28 UTC	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	371	$98.68	$36,611.06	Disclosure SEC source: 0000899243-20-018175 · doc4.xml · nonDerivative · entry 2 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average sale price of the shares sold ranging from $98.50 to $98.725 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the ranges set forth in footnotes 1 through 3. Read SEC document
June 29, 2020 Filed Jul 1, 2020 23:28 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	371	$11.69	$4,336.99	Disclosure SEC source: 0000899243-20-018175 · doc4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 29, 2020 Filed Oct 31, 2020 00:56 UTC Amendment	MyoKardia, Inc. MYOK · Entity 145206	SaleCommon Stock	371	$98.68	$36,611.06	Disclosure SEC source: 0000899243-20-030040 · doc4a.xml · nonDerivative · entry 2 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 F1 · price: Represents the weighted average sale price of the shares sold ranging from $98.50 to $98.725 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the ranges set forth in footnotes 1 through 3. Read SEC document
June 29, 2020 Filed Oct 31, 2020 00:56 UTC Amendment	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	371	$11.69	$4,336.99	Disclosure SEC source: 0000899243-20-030040 · doc4a.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,671 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 18, 2020 Filed Jun 22, 2020 22:58 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantRestricted Stock Units · Derivative	1,800	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017417 · doc4.xml · derivative · entry 2 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800 Underlying: Common Stock · 1,800 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 18, 2020 Filed Jun 22, 2020 22:58 UTC	MyoKardia, Inc. MYOK · Entity 145206	GrantStock Option (Right to Buy) · Derivative	3,000	$0.00 Strike: $100.27	$0.00	Disclosure SEC source: 0000899243-20-017417 · doc4.xml · derivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2030-06-17 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 12 equal monthly installments after June 18, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 13, 2020 Filed Jun 16, 2020 22:00 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	2,300	$0.00	$0.00	Disclosure SEC source: 0000899243-20-016680 · doc4.xml · derivative · entry 2 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 13, 2020 Filed Jun 16, 2020 22:00 UTC	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	2,300	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-016680 · doc4.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: RSUs convert into common stock on a one-for-one basis. Read SEC document
June 13, 2020 Filed Jun 23, 2020 22:37 UTC Amendment	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionRestricted Stock Units · Derivative	2,300	$0.00	$0.00	Disclosure SEC source: 0000899243-20-017512 · doc4a.xml · derivative · entry 2 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,300 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: RSUs convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: 2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). F2 · derivative.expiration_date: 2. Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in a single installment on the first anniversary of the grant date, such that all of the underlying shares shall be vested on June 13, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors. The shares of Common Stock underlying the RSUs are subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2015 Stock Option and Incentive Plan, as amended). Read SEC document
June 13, 2020 Filed Jun 23, 2020 22:37 UTC Amendment	MyoKardia, Inc. MYOK · Entity 145206	Exercise / conversionCommon Stock	2,300	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-017512 · doc4a.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: RSUs convert into common stock on a one-for-one basis. Read SEC document
April 28, 2020 Filed May 1, 2020 00:46 UTC	Chemours Co CC · Entity 4420	GrantCommon Stock	12,820	$0.00	$0.00	Disclosure SEC source: 0001627223-20-000030 · primary_doc.xml · nonDerivative · entry 1 CRANSTON MARY B · CIK 0001104268 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,740 F1 · balance_after: Includes directly owned shares, stock units and dividend equivalent units. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.